1. What isZorequinand for what it is used
2. What you need to know before starting to useZorequin
3. How to useZorequin
4. Possible adverse effects
5. Storage ofZorequin
6. Contents of the package and additional information
Zorequincontains diclofenac sodium as the active ingredient. Diclofenac sodium is an active ingredient anti-inflammatory non-steroidal. This medication is used, applied to the skin, for the treatment of a skin problem known as solar or actinic keratosis caused by prolonged exposure to solar radiation.
Do not use Zorequin:
Warnings and precautions
Consult your doctor or pharmacist before usingZorequin.
Children and adolescents
The safety and efficacy of Zorequin in children have not been established. No data are available.
Other medications and Zorequin
Inform your doctor or pharmacist if you are using, have used recentlyor may need to use any other medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
You should not use Zorequin during the first 6 months of pregnancy unless it is absolutely necessary and your doctor indicates so. If you need treatment during this period or while trying to become pregnant, use the lowest dose (<30>
Do not use Zorequin if you are in the last 3 months of pregnancy, as it may harm the fetus or cause complications during delivery.
Breastfeeding
Small amounts of diclofenac pass into breast milk. Consult your doctor if you are breastfeeding.Zorequinmay be used during breastfeeding, but do not apply it directly to the breast area or to large skin areas or for a prolonged period.
Driving and operating machinery
Zorequin does not affect your ability to drive or operate machinery.
Zorequin contains benzyl alcohol
This medication contains 10 mg of benzyl alcohol per g of gel. Benzyl alcohol may cause allergic reactions and mild local irritation.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The usual treatment period is 60 to 90 days. The maximum effect has been observed in treatments of a duration close to 90 days. It may take up to 1 month from the end of treatment for complete healing.
Use in children and adolescents
Diclofenac is not suitable for children or adolescents.
If you use more Zorequin than you should
Remove any excess gel by washing the treated skin area with water.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to use Zorequin
Continue applying as instructed, but do not apply a double dose of gel to compensate for the missed application.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
If you experience any of the following side effects, stop using Zorequin and inform your doctor as soon as possible:
Skin rash (urticaria); difficulty breathing (sibilant breathing); facial swelling, nasal discharge (allergic rhinitis) (very rare side effects, may affect up to 1 in 10,000 people). These symptoms indicate that you may be allergic to Zorequin.
If you consider any of the following side effects you are experiencing to be severe or persistent for more than a few days, stop using Zorequin and inform your doctor: itching, skin reaction, skin redness, inflammation, contact dermatitis, pain, and blisters.
Other frequent side effects:(may affect up to 1 in 10 people)
Irritation or tingling in the treated area, conjunctivitis, allergy, painful sensation when touching the skin, pinpricks, muscle stiffness, dermatitis, eczema, dry skin, swelling, generalized redness (covered in scales or blisters), skin thickening, and skin ulcer.
Less frequent side effects:(may affect up to 1 in 100 people)
Eye pain, excessive tearing/dry eyes, excessive bleeding, abdominal pain, diarrhea, nausea, hair loss, facial edema, excessive bleeding, greasy skin, or skin rash similar to measles.
Rare side effects:(may affect up to 1 in 1,000 people)
Large blistering dermatitis.
Very rare side effects:(may affect up to 1 in 10,000 people)
Stomach bleeding, kidney problems, difficulty breathing (asthma), skin rash with infection, skin sensitivity to sunlight.
There have been reported cases of temporary hair discoloration in the application area. This effect is usually reversible upon discontinuing treatment.
Unknown frequency (cannot be estimated from available data):Burning sensation at the application site
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the tube or the container, after CAD or EXP. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C.
Keep the tube hermetically closed to protect it from light.
Once the product is opened, use within: 6 months.
Medications should not be thrown down the drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE point of the pharmacy.Ask your pharmacist how to dispose of the containers and medications you no longer need. This will help protect the environment.
Composition of Zorequin
Appearance of Zorequin and content of the packaging
Clear, transparent, colorless, or pale yellow gel packaged in tubes with a content of 25 grams, 50 grams, 60 grams, 90 grams, or 100 grams of gel.
Not all packaging sizes may be marketed.
Holder of the marketing authorization
Teva Pharma, S.L.U.
C/ Anabel Segura, 11 - Edificio Albatros B, 1st floor.
28108 – Alcobendas. Madrid
Spain
Responsible for manufacturing
Balkanpharma Troyan AD, 1 Krayrechna Str., Troyan 5600,
Bulgaria
Local representative
Industrial Farmacéutica Cantabria, S.A.
Barrio Solía 30
La Concha de Villaescusa
39690 Cantabria (Spain)
This medicine is authorized in the Member States of the European Economic Area with the following names:
DE: Diclofenac-ratiopharm 30mg/g Gel
ES: Zorequin 30 mg/g gel
LU:Diclofenac-ratiopharm Dermagel 30mg/g Gel
Last review date of this leaflet:December 2023
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.